We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

129 hedge funds and large institutions have $340M invested in Karyopharm Therapeutics in 2023 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 52 increasing their positions, 30 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

101% more call options, than puts

Call options by funds: $1.03M | Put options by funds: $515K

73% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 30

2% more capital invested

Capital invested by funds: $334M → $340M (+$5.77M)

0.65% less ownership

Funds ownership: 5.79% → 5.15% (-0.65%)

16% less funds holding

Funds holding: 154 → 129 (-25)

58% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 43

Holders
129
Holders Change
-25
Holders Change %
-16.23%
% of All Funds
2.06%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
18
Increased
52
Reduced
30
Closed
43
Calls
$1.03M
Puts
$515K
Net Calls
+$519K
Net Calls Change
-$184K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$7.59M
2
State Street
State Street
Massachusetts
+$6.22M
3
Barclays
Barclays
United Kingdom
+$5.93M
4
OM
Opaleye Management
Massachusetts
+$5.28M
5
SCM
Silverarc Capital Management
Massachusetts
+$5.07M

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$13.1M
2
RCMNY
Rubric Capital Management (New York)
New York
-$12.7M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$6.77M
4
CC
Commodore Capital
New York
-$6.58M
5
ITP
Iron Triangle Partners
Connecticut
-$6.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
AF
126
Allworth Financial
California
$1.95K – – –
LC
127
Lindbrook Capital
California
$1.55K +$1.33K +27 New
QC
128
Quent Capital
New York
$1.5K – – –
Daiwa Securities Group
129
Daiwa Securities Group
Japan
$1K – – –
KFS
130
Kelly Financial Services
Massachusetts
$973 – – –
FGAM
131
Financial Gravity Asset Management
Texas
$8 – – –
CFGS
132
Concourse Financial Group Securities
Alabama
$3 – – –
AC
133
Armistice Capital
New York
– -$13.1M -256,904 Closed
Point72 Asset Management
134
Point72 Asset Management
Connecticut
– -$6.77M -132,774 Closed
CC
135
Commodore Capital
New York
– -$6.58M -129,041 Closed
ITP
136
Iron Triangle Partners
Connecticut
– -$6.55M -128,452 Closed
WP
137
Woodline Partners
California
– -$4.5M -88,326 Closed
CH
138
CVI Holdings
Delaware
– -$4.26M -83,494 Closed
ECM
139
ExodusPoint Capital Management
New York
– -$3.76M -73,742 Closed
ABG
140
Ally Bridge Group
New York
– -$3.05M -59,775 Closed
Acadian Asset Management
141
Acadian Asset Management
Massachusetts
– -$2.87M -56,383 Closed
Adage Capital Partners
142
Adage Capital Partners
Massachusetts
– -$2.62M -51,381 Closed
Qube Research & Technologies (QRT)
143
Qube Research & Technologies (QRT)
United Kingdom
– -$1.78M -34,919 Closed
CSS
144
Cubist Systematic Strategies
Connecticut
– -$1.67M -32,667 Closed
MIM
145
Monashee Investment Management
Massachusetts
– -$1.64M -32,113 Closed
Two Sigma Investments
146
Two Sigma Investments
New York
– -$902K -17,687 Closed
XT
147
XTX Topco
Cayman Islands
– -$445K -8,721 Closed
Jane Street
148
Jane Street
New York
– -$320K -6,489 Closed
GCP
149
GSA Capital Partners
United Kingdom
– -$279K -5,477 Closed
NYLIM
150
New York Life Investment Management
New York
– -$262K -5,131 Closed
3 4 5
6
7

KPTI Hedge Fund Activity: Q1 2023 in Review

129 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2023, worth a combined $340M — up 1.7% from $334M a quarter earlier.

Sellers outnumbered buyers: 43 funds closed out of KPTI and 18 opened new positions — a net loss of 25 holders — while 30 trimmed existing stakes and 52 added.

The largest buyer was Vanguard Group, adding an estimated $7.59M. The largest seller was Armistice Capital, exiting entirely with an estimated $13.1M sold.

  • 129 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2023, down from 154 in Q4 2022.
  • Funds reported $340M of Karyopharm Therapeutics stock for Q1 2023, up 1.7% quarter-over-quarter.
  • 18 funds opened new Karyopharm Therapeutics positions in Q1 2023 and 43 closed out, a net change of -25 holders.
  • The largest Karyopharm Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $7.59M added.
  • The largest Karyopharm Therapeutics seller in Q1 2023 was Armistice Capital, an estimated $13.1M sold.

Based on aggregated 13F filings for Q1 2023.